<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796872</url>
  </required_header>
  <id_info>
    <org_study_id>CLA12016CN</org_study_id>
    <nct_id>NCT02796872</nct_id>
  </id_info>
  <brief_title>The Effect of Feeding Infant Formula With Bimuno Galactooligosaccharide (GOS)</brief_title>
  <official_title>The Effect of Feeding Infant Formula With Bimuno Galactooligosaccharide (GOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clasado</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clasado</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This survey is a multicenter, double-blind, randomized, controlled, parallel-designed,
      prospective trial and is intended to evaluate the Bimuno GOS effects on growth, tolerance,
      gut health, fecal flora and immune function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anthropometric parameters</measure>
    <time_frame>6 months</time_frame>
    <description>body length, body weight, and head circumferences at enrollment (15± 3 days of age), 30, 60, 90, 120, 150 and 180 days of age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal bacteria analysis</measure>
    <time_frame>6 months</time_frame>
    <description>o Fecal bacteria analysis of Bifidobacterium, Lactobacillus, Clostridium perfringens and Escherichia coli at the enrollment 30 days of age ,120 days of age and 180 days of age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary</measure>
    <time_frame>6 months</time_frame>
    <description>tool characteristics, tolerance, formula acceptance, stress and 3-day well-being (quality of life) questionnaire prior to each survey visit recorded at 30, 60, 90, 120, 150 and 180 days of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formula intake</measure>
    <time_frame>6 months</time_frame>
    <description>Formula intake (24-hour dietary recall) at 30, 60, 90, 120, 150 and 180 days of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All medically confirmed adverse events and antibiotic record</measure>
    <time_frame>6 months</time_frame>
    <description>All medically confirmed adverse events including crying, gaseous colics, regurgitation, vomit, skin rashes, fever and concomitant medications recorded on medical records as a measure of safety and tolerability throughout the survey period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal sIgA and SCFA analysis</measure>
    <time_frame>6 months</time_frame>
    <description>Fecal sIgA and SCFA analysis at 30 days of age (visit 1) and 180 days of age (visit 6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saliva cortisol, IgA, chromogranin A and lysozyme</measure>
    <time_frame>6 months</time_frame>
    <description>Saliva cortisol, IgA, chromogranin A and lysozyme at 30, 90 and 180 days of age</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Dietary Modification</condition>
  <arm_group>
    <arm_group_label>mother's breast milk.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>mother's breast milk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>other GOS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercial infant formula containing 4% w/w FOS:GOS (1:3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-GOS 3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-GOS 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GOS</intervention_name>
    <description>GOS resource (β-galactosidase from Bacillus circulans) Commercial infant formula containing 4% w/w FOS:GOS (1:3)</description>
    <arm_group_label>other GOS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>B-GOS 3%</intervention_name>
    <description>Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)</description>
    <arm_group_label>B-GOS 3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>B-GOS 2%</intervention_name>
    <description>Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)</description>
    <arm_group_label>B-GOS 2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mother's breast milk</intervention_name>
    <description>exclusively breastfed infants for at least 7 days prior to enrollment</description>
    <arm_group_label>mother's breast milk.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  o 15 ± 3 days of age at randomization, inclusive (day of birth is considered day 0)

               -  Singleton birth

               -  Gestational age of 37-42 weeks (36 weeks and six days is considered 36 weeks
                  gestational age)

               -  Birth weight of 2500g to 4000g

               -  Signed informed consent obtained for infant's participation in the survey

               -  Parent or guardian of infant agrees not to enroll infant in another
                  interventional clinical research survey while participating in this survey

               -  APGAR score after 5 minutes of life &gt; 7

               -  Consuming only one source of nutrition

               -  Formula-fed infant: Infant consuming infant formula as the sole source of
                  nutrition for 7 consecutive days prior to randomization

               -  Breastfed infant: Infant consuming mother's breast milk as the sole source of
                  nutrition for 7 consecutive days prior to registration

        Exclusion Criteria:

          -  Infant with inborn malformation and with hereditary and/or chronic and/or inborn
             diseases requiring hospital care superior to 7 days

          -  Diseases jeopardizing intrauterine growth

          -  Weight at Visit 1 is &lt;95% of birth weight [(weight at Visit 1÷birth weight) x 100
             &lt;95%]

          -  Infant born from mother suffering from metabolic and/or chronic diseases

          -  Infant with an acute infection or gastroenteritis at time of randomization or
             registration

          -  Infant consuming supplemental foods

          -  Evidence of feeding difficulties or formula intolerance, such as vomiting or poor
             intake at time of randomization or registration

          -  Infant is immunocompromised (according to a doctor's diagnosis of immunodeficiency
             such as Combined Immunodeficiencies, DiGeorge Syndrome, Wiskott-Aldrich Syndrome,
             Severe Congenital Neutropenia and Secondary Immunodeficiencies linked to HIV
             infection, Down Syndrome or others) and children with known head/brain disease/injury
             such as Microcephaly, Macrocephaly or others
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

